Palisade Bio (PALI) 10-Q 14 Nov 19 2019 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 05, 2019
Document Information [Line Items]
Entity Registrant Name	Neuralstem, Inc.
Entity Central Index Key	0001357459
Trading Symbol	cur
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		3,866,457
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Amendment Flag	false
Title of 12(b) Security	Common Stock, $0.01 par value

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2019	Dec. 31, 2018
CURRENT ASSETS
Cash and cash equivalents	$ 7,299,836	$ 5,787,110
Trade and other receivables	61,154	294,057
Current portion of related party receivable, net of discount		63,938
Prepaid expenses	605,312	363,288
Total current assets	7,966,302	6,508,393
Property and equipment, net	51,943	90,311
Patents, net	688,127	763,543
Related party receivable, net of discount and current portion		298,238
ROU and other assets	237,141	23,965
Total assets	8,943,513	7,684,450
CURRENT LIABILITIES
Accounts payable and accrued expenses	1,181,364	832,564
Short term note and other current liabilities	400,016	218,602
Total current liabilities	1,581,380	1,051,166
Warrant liabilities, at fair value	166,938	583,734
Lease liability, net of current portion	152,632
Total liabilities	1,900,950	1,634,900
Commitments and contingencies (Note 5)
STOCKHOLDERS' EQUITY
Preferred stock, 7,000,000 shares authorized, $0.01 par value; 200,000 and 1,000,000 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively	2,000	10,000
Common stock, $0.01 par value; 300,000,000 shares authorized, 2,818,291 and 910,253 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively	28,183	9,103
Additional paid-in capital	226,957,990	219,654,753
Accumulated other comprehensive loss	(7,670)	(413)
Accumulated deficit	(219,937,940)	(213,623,893)
Total stockholders' equity	7,042,563	6,049,550
Total liabilities and stockholders' equity	$ 8,943,513	$ 7,684,450

Unaudited Condensed Consolida_2

Unaudited Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	7,000,000	7,000,000
Preferred stock, shares issued (in shares)	200,000	1,000,000
Preferred stock, shares outstanding (in shares)	200,000	1,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Common stock, shares issued (in shares)	2,818,291	910,253
Common stock, shares outstanding (in shares)	2,818,291	910,253

Unaudited Condensed Consolida_3

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenues	$ 2,500	$ 2,500	$ 12,894	$ 257,500
Operating expenses:
Research and development expenses	825,486	897,098	3,294,402	3,081,319
General and administrative expenses	1,301,189	1,188,076	3,217,613	3,630,822
Total operating expenses	2,126,675	2,085,174	6,512,015	6,712,141
Operating loss	(2,124,175)	(2,082,674)	(6,499,121)	(6,454,641)
Other income (expense):
Interest income	15,234	17,619	55,086	54,882
Interest expense	(1,913)	(1,498)	(4,437)	(4,190)
Change in fair value of derivative instruments	320,785	236,270	416,796	1,805,319
Other income (expense)	26,935		(282,371)	(5,667)
Total other income	361,041	252,391	185,074	1,850,344
Net loss	$ (1,763,134)	$ (1,830,283)	$ (6,314,047)	$ (4,604,297)
Net loss per share - basic and diluted (in dollars per share)	$ (0.59)	$ (2.41)	$ (4.80)	$ (6.08)
Weighted average common shares outstanding - basic and diluted (in shares)	2,975,779	758,575	1,316,597	757,221
Comprehensive loss:
Net loss	$ (1,763,134)	$ (1,830,283)	$ (6,314,047)	$ (4,604,297)
Foreign currency translation adjustment	(4,501)	(512)	(7,257)	(2,001)
Comprehensive loss	$ (1,767,635)	$ (1,830,795)	$ (6,321,304)	$ (4,606,298)

Unaudited Consolidated Statemen

Unaudited Consolidated Statements of Changes In Stockholders' Equity - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2017	1,000,000	758,001
Balance at Dec. 31, 2017	$ 10,000	$ 7,580	$ 217,194,194	$ 2,631	$ (208,699,276)	$ 8,515,129
Share based payments			238,835			238,835
Foreign currency translation adjustments				115		115
Net loss					(2,146,968)	(2,146,968)
Balance (in shares) at Mar. 31, 2018	1,000,000	758,001
Balance at Mar. 31, 2018	$ 10,000	$ 7,580	217,433,029	2,746	(210,846,244)	6,607,111
Balance (in shares) at Dec. 31, 2017	1,000,000	758,001
Balance at Dec. 31, 2017	$ 10,000	$ 7,580	217,194,194	2,631	(208,699,276)	8,515,129
Net loss						(4,604,297)
Balance (in shares) at Sep. 30, 2018	1,000,000	758,001
Balance at Sep. 30, 2018	$ 10,000	$ 7,580	217,764,467	630	(213,303,573)	4,479,104
Balance (in shares) at Mar. 31, 2018	1,000,000	758,001
Balance at Mar. 31, 2018	$ 10,000	$ 7,580	217,433,029	2,746	(210,846,244)	6,607,111
Share based payments			196,742			196,742
Foreign currency translation adjustments				(1,604)		(1,604)
Net loss					(627,046)	(627,046)
Balance (in shares) at Jun. 30, 2018	1,000,000	758,001
Balance at Jun. 30, 2018	$ 10,000	$ 7,580	217,629,771	1,142	(211,473,290)	6,175,203
Share based payments			134,696			134,696
Foreign currency translation adjustments				(512)		(512)
Net loss					(1,830,283)	(1,830,283)
Balance (in shares) at Sep. 30, 2018	1,000,000	758,001
Balance at Sep. 30, 2018	$ 10,000	$ 7,580	217,764,467	630	(213,303,573)	4,479,104
Balance (in shares) at Dec. 31, 2018	1,000,000	910,253
Balance at Dec. 31, 2018	$ 10,000	$ 9,103	219,654,753	(413)	(213,623,893)	6,049,550
Share based payments			337,966			337,966
Foreign currency translation adjustments				(1,743)		(1,743)
Net loss					(3,113,992)	(3,113,992)
Balance (in shares) at Mar. 31, 2019	1,000,000	910,253
Balance at Mar. 31, 2019	$ 10,000	$ 9,103	219,992,719	(2,156)	(216,737,885)	3,271,781
Balance (in shares) at Dec. 31, 2018	1,000,000	910,253
Balance at Dec. 31, 2018	$ 10,000	$ 9,103	219,654,753	(413)	(213,623,893)	6,049,550
Net loss						(6,314,047)
Balance (in shares) at Sep. 30, 2019	200,000	2,818,291
Balance at Sep. 30, 2019	$ 2,000	$ 28,183	226,957,990	(7,670)	(219,937,940)	7,042,563
Balance (in shares) at Mar. 31, 2019	1,000,000	910,253
Balance at Mar. 31, 2019	$ 10,000	$ 9,103	219,992,719	(2,156)	(216,737,885)	3,271,781
Share based payments			128,778			128,778
Foreign currency translation adjustments				(1,013)		(1,013)
Net loss					(1,436,921)	(1,436,921)
Issuance of common stock for conversion of Series A Preferred Stock (in shares)	(465,191)	90,419
Issuance of common stock for conversion of Series A Preferred Stock	$ (4,652)	$ 904	3,748
Issuance of common stock for RSU exercises (in shares)		1,126
Issuance of common stock for RSU exercises		$ 11	(11)
Balance (in shares) at Jun. 30, 2019	534,809	1,001,798
Balance at Jun. 30, 2019	$ 5,348	$ 10,018	220,125,234	(3,169)	(218,174,806)	1,962,625
Share based payments			294,600			294,600
Foreign currency translation adjustments				(4,501)		(4,501)
Net loss					(1,763,134)	(1,763,134)
Issuance of common stock for conversion of Series A Preferred Stock (in shares)	(334,809)	65,077
Issuance of common stock for conversion of Series A Preferred Stock	$ (3,348)	$ 651	2,697
Share rounding adjustment related to 1:20 reverse stock split (in shares)		6,117
Share rounding adjustment related to 1:20 reverse stock split		$ 61	(61)
Issuance of common stock and warrants from capital raises, net (in shares)		416,315
Issuance of common stock and warrants from capital raises, net		$ 4,163	6,548,679			6,552,842
Issuance of restricted stock awards (in shares)		15,688
Issuance of restricted stock awards		$ 157	(157)
Issuance of common stock for warrant exercises (in shares)		1,313,296
Issuance of common stock for warrant exercises		$ 13,133	(13,002)			131
Balance (in shares) at Sep. 30, 2019	200,000	2,818,291
Balance at Sep. 30, 2019	$ 2,000	$ 28,183	$ 226,957,990	$ (7,670)	$ (219,937,940)	$ 7,042,563

Unaudited Condensed Consolida_4

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities:
Net loss	$ (6,314,047)	$ (4,604,297)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization	113,735	160,464
Share-based compensation expense	761,344	570,273
Allowance for bad debt	362,176
Change in fair value of liability classified warrants	(416,796)	(1,805,319)
Changes in operating assets and liabilities:
Trade and other receivables	232,903	150,823
Related party receivable		71,638
Prepaid expenses	(235,946)	(154,271)
ROU and other assets	24,938	(4,000)
Accounts payable and accrued expenses	340,673	(25,487)
Accrued bonuses		(418,625)
Other current liabilities	(48,110)	26,288
Lease and other long term liabilities	(27,618)	(1,876)
Net cash used in operating activities	(5,206,748)	(6,034,389)
Cash flows from investing activities:
Maturity of short-term investments		5,000,000
Net cash provided by investing activities		5,000,000
Cash flows from financing activities:
Net proceeds from the sale of our common stock and warrants	6,552,842
Proceeds from warrant exercises	131
Proceeds from short-term note payable	414,320	349,578
Payments of short-term note payable	(241,061)	(247,817)
Net cash provided by financing activities	6,726,232	101,761
Effects of exchange rates on cash	(6,758)	(5,383)
Net increase (decrease) in cash and cash equivalents	1,512,726	(938,011)
Cash and cash equivalents, beginning of period	5,787,110	6,674,940
Cash and cash equivalents, end of period	7,299,836	5,736,929
Supplemental disclosure of cash flows information:
Cash paid for interest	$ 4,437	$ 4,190

Note 1 - Organization, Business

Note 1 - Organization, Business and Financial Condition	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. Organization, Business and Financial Condition Nature of business In October 2019, one Seneca Biopharma, Inc., is a clinical-stage biopharmaceutical company developing novel treatments for various diseases of high unmet medical need. The Company is in the process of transforming the organization through the acquisition or in-licensing of new science and technologies, to develop with the goal of providing meaningful therapies for patients. On October 31, 2019 no In addition to the anticipated development of in-licensed or acquired technologies, the Company plans to continue to maintain NSI- 566 189 The Company was founded in 1997 On July 17, 2019 1 20 1 20 Liquidity and Going Concern The Company has incurred losses since its inception and has not not no one not In making this assessment we performed a comprehensive analysis of our current circumstances including: our financial position at September 30, 2019, one 10 July 2019, $6.6 4 We expect that our existing cash and cash equivalents will be sufficient to enable us to fund our anticipated level of operations based on our current operating plans into the third 2020. no not may third not We have spent and will continue to spend substantial funds in the research, development, pre-clinical and clinical testing of our small molecule and stem cell product candidates and we anticipate spending additional funds to maintain these programs as we seek partners to further their clinical development. Additionally, if the QYuns transaction is consummated, we anticipate spending substantial funds on the development of the in-licensed programs with the goal of ultimately obtaining approval from the United States Food and Drug Administration (the “FDA”) and its international equivalents regulatory agencies, to market and sell our products. We have also begun spending funds on the evaluation and new assets and technologies with the goal of acquisition and development. No

Note 2 - Significant Accounting

Note 2 - Significant Accounting Policies and Basis of Presentation	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 2. Basis of Presentation In management’s opinion, the accompanying interim unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. The unaudited condensed consolidated balance sheet at December 31, 2018, not may not 10 December 31, 2018, may Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The unaudited condensed consolidated financial statements include significant estimates for the expected economic life and value of our licensed technology and related patents, our net operating loss and related valuation allowance for tax purposes, the fair value of our liability classified warrants and our share-based compensation related to employees and directors, consultants and advisors, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates. Fair Value Measurements The carrying amounts of our short-term financial instruments, which primarily include cash and cash equivalents, short-term investments, accounts payable and accrued expenses, approximate their fair values due to their short maturities. The fair value of our long-term indebtedness was estimated based on the quoted prices for the same or similar issues or on the current rates offered to the Company for debt of the same remaining maturities and approximates the carrying value. The fair values of our liability classified warrants were estimated using Level 3 3 Foreign Currency Translation The functional currency of our wholly owned foreign subsidiary is its local currency. Assets and liabilities of our foreign subsidiary are translated into United States dollars based on exchange rates at the end of the reporting period; income and expense items are translated at the weighted average exchange rates prevailing during the reporting period. Translation adjustments for subsidiary are accumulated in other comprehensive income or loss, a component of stockholders' equity. Transaction gains or losses are included in the determination of net loss. Cash, Cash Equivalents and Credit Risk Cash equivalents consist of investments in low risk, highly liquid money market accounts and certificates of deposit with original maturities of 90 may Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents. Our investment policy, approved by our Board of Directors, limits the amount we may one not Revenue The Company analyzes contracts to determine the appropriate revenue recognition using the following steps: (i) identification of contracts with customers; (ii) identification of distinct performance obligations in the contract; (iii) determination of contract transaction price; (iv) allocation of contract transaction price to the performance obligations; and (v) determination of revenue recognition based on timing of satisfaction of the performance obligation. The Company recognizes revenues upon the satisfaction of its performance obligation (upon transfer of control of promised goods or services to customers) in an amount that reflects the consideration to which it expects to be entitled to in exchange for those goods or services. Deferred revenue results from cash receipts from or amounts billed to customers in advance of the transfer of control of the promised services to the customer and is recognized as performance obligations are satisfied. When sales commissions or other costs to obtain contracts with customers are considered incremental and recoverable, those costs are deferred and then amortized as selling and marketing expenses on a straight-line basis over an estimated period of benefit. Research and Development Research and development costs are expensed as they are incurred. Research and development expenses consist primarily of costs associated with the pre-clinical development and clinical trials of our product candidates. For the nine September 30, 2019 2018, $382,000 $318,000, Income (Loss) per Common Share Basic income (loss) per common share is computed by dividing total net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period. Weighted average shares outstanding includes outstanding “prefunded” warrants with an exercise price of $0.0001. 4 For periods of net income when the effects are dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted average number of shares outstanding and the dilutive impact of all dilutive potential common shares. Dilutive potential common shares consist primarily of convertible preferred stock, stock options, restricted stock units and common stock purchase warrants. The dilutive impact of potential common shares resulting from common stock equivalents is determined by applying the treasury stock method. Our unvested restricted shares contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; the calculation of basic and diluted income per share excludes net income attributable to the unvested restricted shares from the numerator and excludes the impact of the shares from the denominator. For all periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive due to the net losses; accordingly, diluted loss per share is the same as basic loss per share for the three nine September 30, 2019 2018. 7.3 0.5 three nine September 30, 2019 2018, Share-Based Compensation We account for share-based compensation at fair value. Share-based compensation cost for stock options and stock purchase warrants is generally determined at the grant date using an option pricing model that uses Level 3 Intangible and Long-Lived Assets We assess impairment of our long-lived assets using a "primary asset" approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not not No three nine September 30, 2019 2018. Income Taxes We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is “more likely than not” Leases We determine if an arrangement is or contains a lease at its inception. We have made accounting policy elections whereby we (i) do not 12 not ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Rent expense is recognized on a straight-line basis over the lease term. See Note 5, Significant New Accounting Pronouncements Recently Adopted Guidance In February 2016, ASU, No. 2016 02, December 15, 2018 may January 1, 2019 not not $53,000 $75,700 In June 2018, ASU 2018 07, ASC 718, 1 2 3 December 15, 2018. January 1, 2019. not Unadopted Guidance In June 2016, ASU No. 2016 13, December 15, 2019, not In August 2018, ASU 2018 13, 820 December 15, 2019 In August 2018, ASU 2018 15, December 15, 2019 We have reviewed other recent accounting pronouncements and concluded that they are either not no

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 3. Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These levels are: · Level 1 · Level 2 not · Level 3 Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis We have segregated our financial assets and liabilities that are measured at fair value on a recurring into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date. At September 30, 2019 December 31, 2018, May 2016 August 2017 4 3 Level 1 Level 2 Level 3 Total Liabilities Liability classified stock purchase warrants $ - $ - $ 583,734 $ 583,734 Balance at December 31, 2018 $ - $ - $ 583,734 $ 583,734 Liability classified stock purchase warrants $ - $ - $ 166,938 $ 166,938 Balance at September 30, 2019 $ - $ - $ 166,938 $ 166,938 The following table presents the activity for those items measured at fair value on a recurring basis using Level 3 nine September 30, 2019: Mark-to-market liabilities - stock purchase warrants Balance at December 31, 2018 $ 583,734 Change in fair value - gain (416,796 ) Balance at September 30, 2019 $ 166,938 The following table presents the activity for those items measured at fair value on a recurring basis using Level 3 nine September 30, 2018: Mark-to-market liabilities - stock purchase warrants Balance at December 31, 2017 $ 3,852,882 Change in fair value - gain (1,805,319 ) Balance at September 30, 2018 $ 2,047,563 The (gains) losses resulting from the changes in the fair value of the liability classified warrants are classified as other income or expense in the accompanying unaudited condensed consolidated statements of operations. The fair value of the common stock purchase warrants is determined based on the Black-Scholes option pricing model or other option pricing models as appropriate and includes the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends. Changes in any of the assumptions related to the unobservable inputs identified above may

Note 4 - Stockholders' Equity

Note 4 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	Note 4. We have granted share-based compensation awards to employees, board members and service providers. Awards may ten September 30, 2019, 8.5 We typically record share-based compensation expense on a straight-line basis over the requisite service period. Share-based compensation expenses included in the statements of operations are as follows: Three Months Ended September 30, 2019 2018 Research and development expenses $ - $ 22,917 General and administrative expenses 294,600 111,778 Total $ 294,600 $ 134,695 Nine Months Ended September 30, 2019 2018 Research and development expenses $ 200,337 $ 110,417 General and administrative expenses 561,007 459,856 Total $ 761,344 $ 570,273 Stock Options A summary of stock option activity and related information for the nine September 30, 2019 Number of Options Weighted-Average Exercise Price Weighted-Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding at January 1, 2019 81,674 $ 215.60 5.1 $ - Granted 228,183 $ 7.78 Exercised - $ - $ - Forfeited (10,127 ) $ 86.07 Outstanding at September 30, 2019 299,730 $ 61.78 7.9 $ - Exercisable at September 30, 2019 206,347 $ 86.15 7.2 $ - Range of Exercise Prices Number of Options Outstanding Weighted-Average Exercise Price Weighted-Average Remaining Contractual Life (in years) Aggregate Intrinsic Value $5.90 - $6.00 58,010 $ 5.99 9.3 $ - $7.20 - $8.80 162,593 $ 8.51 9.2 - $22.20 - $99.20 36,138 $ 33.20 5.6 - $107.40 - $1,102.41 42,989 $ 362.61 2.9 - 299,730 $ 61.78 7.9 $ - The Company uses the Black-Scholes option pricing model for “plain vanilla” options and other pricing models as appropriate to calculate the fair value of options. The Company generally uses the “simplified method” to estimate expected life. Significant assumptions used in these models include: Nine Months Ended September 30, 2019 2018 Annual dividend - - Expected life (in years) 4.8 - 5.5 2.5 - 5.3 Risk free interest rate 1.8% - 2.5% 2.7% - 2.8% Expected volatility 97% - 115% 97% - 117% Options granted in the nine September 30, 2019 2018, $3.45 $15.40 Unrecognized compensation cost for unvested stock option awards outstanding at September 30, 2019 $384,000 0.7 In the three March 31, 2019, $102,000 three March 31, 2019. RSUs We have granted restricted stock units (RSUs) to certain employees and board members that entitle the holders to receive shares of our common stock upon vesting and subject to certain restrictions regarding the exercise of the RSUs. The grant date fair value of RSUs is based upon the market price of the underlying common stock on the date of grant. In the nine September 30, 2019 2018, 4,904 2,253 nine September 30, 2019 2018, $5.90 $22.20, RSUs vesting in the nine September 30, 2019 $6,400. At September 30, 2019, 5,467 $29.62 $10,400. September 30, 2019 $22,000 0.8 In the nine September 30, 2019, 1,127 $10,400 No nine September 30, 2018. Restricted Stock We have granted restricted stock to certain board members that vest quarterly over the grant year. The grant date fair value of the restricted stock is based upon the market price of the common stock on the date of grant. In the nine September 30, 2019 2018, 15,689 2,253 nine September 30, 2019 2018, $5.95 $22.20, Restricted stock vesting in the nine September 30, 2019, $9.73 $14,500. At September 30, 2019, 11,972 $5.95. September 30, 2019 $71,300 0.8 Stock Purchase Warrants. We have issued warrants to purchase common stock to certain officers, directors, stockholders and service providers as well as in conjunction with debt and equity offerings and at various times replacement warrants were issued as an inducement for warrant exercises. In May 2016 August 2017, 87,309 112,500 contained in the warrants. At September 30, 2019, 149,136 3 In February 2019, 25,000 third $6.00, January 2024 $3.80 25% 75% September 30, 2019. no 2.5 2.5% 110%. In July 2019, 3,194,443 $2.70 December 31, 2020; ( 3,194,443 $2.70 5 2,361,462 $0.0001 no September 30, 2019, 1,313,296 $100 In connection with the July 222,223 $3.375 5 A summary of outstanding warrants at September 30, 2019 Range of Exercise Prices Number of Warrants Outstanding Range of Expiration Dates $0.0001 1,048,166 perpetual $2.19 - $2.70 6,538,035 December 2020 - August 2024 $3.38 - $17.50 406,223 October 2023 - July 2024 $22.20 - $782.60 26,479 October 2019 - July 2023 8,018,903 Preferred and Common Stock We have outstanding 200,000 4.5% December 2016. 4.5% 38,873 July 2019, 334,809 4.5% 65,077 In July 2019, 416,315 2,361,462 $2.70 $7.5 one one one one one one $0.0001 $2.70 December 31, 2020 five $6.6 416,666 416,666 1 no. 333 232273

Note 5 - Commitments and Contin

Note 5 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 5. Leases We currently operate one one Our corporate offices and primary research facilities are located in Germantown, Maryland, where we lease approximately 1,500 $5,700 12 December 31, 2019. not We also lease approximately 11,300 September 2019, $4,400 September 2024 first Our long-term operating lease and related sublease for our San Diego facility both terminated in August 2019. $86,100 nine September 30, 2019. We recognized total rent expense of approximately $164,500 $134,100 nine September 30, 2019 2018, 2019 $83,900 nine September 30, 2019 Operating lease cost $ 141,300 Variable lease cost 23,200 Sublease income (86,100 ) Total net lease cost $ 78,400 In the nine September 30, 2019, $204,300 At September 30, 2019, $204,300 $183,500 12.75%. Maturities of our lone long-term operating lease as of September 30, 2019 Future undiscounted cash flows: Remainder 2019 $ 11,845 2020 52,482 2021 53,498 2022 55,118 2023 56,920 2024 13,390 Total 243,253 Discount factor (59,733 ) Lease liability 183,520 Less current liability (30,888 ) Non-current lease liability $ 152,632 Other From time to time, we are parties to legal proceedings that we believe to be ordinary, routine litigation incidental to the business. We are currently not

Note 6 - Related Party Receivab

Note 6 - Related Party Receivable	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 6. On August 10, 2016, six $658,000 The $658,000 $199,000 In March 2019, 50% $229,000 September 30, 2019, $229,000 July 2025. not

Note 7 - Subsequent Events

Note 7 - Subsequent Events	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	Note 7. Effective October 28, 2019,

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation In management’s opinion, the accompanying interim unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. The unaudited condensed consolidated balance sheet at December 31, 2018, not may not 10 December 31, 2018, may
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The unaudited condensed consolidated financial statements include significant estimates for the expected economic life and value of our licensed technology and related patents, our net operating loss and related valuation allowance for tax purposes, the fair value of our liability classified warrants and our share-based compensation related to employees and directors, consultants and advisors, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements The carrying amounts of our short-term financial instruments, which primarily include cash and cash equivalents, short-term investments, accounts payable and accrued expenses, approximate their fair values due to their short maturities. The fair value of our long-term indebtedness was estimated based on the quoted prices for the same or similar issues or on the current rates offered to the Company for debt of the same remaining maturities and approximates the carrying value. The fair values of our liability classified warrants were estimated using Level 3 3
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation The functional currency of our wholly owned foreign subsidiary is its local currency. Assets and liabilities of our foreign subsidiary are translated into United States dollars based on exchange rates at the end of the reporting period; income and expense items are translated at the weighted average exchange rates prevailing during the reporting period. Translation adjustments for subsidiary are accumulated in other comprehensive income or loss, a component of stockholders' equity. Transaction gains or losses are included in the determination of net loss.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash, Cash Equivalents and Credit Risk Cash equivalents consist of investments in low risk, highly liquid money market accounts and certificates of deposit with original maturities of 90 may Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents. Our investment policy, approved by our Board of Directors, limits the amount we may one not
Revenue from Contract with Customer [Policy Text Block]	Revenue The Company analyzes contracts to determine the appropriate revenue recognition using the following steps: (i) identification of contracts with customers; (ii) identification of distinct performance obligations in the contract; (iii) determination of contract transaction price; (iv) allocation of contract transaction price to the performance obligations; and (v) determination of revenue recognition based on timing of satisfaction of the performance obligation. The Company recognizes revenues upon the satisfaction of its performance obligation (upon transfer of control of promised goods or services to customers) in an amount that reflects the consideration to which it expects to be entitled to in exchange for those goods or services. Deferred revenue results from cash receipts from or amounts billed to customers in advance of the transfer of control of the promised services to the customer and is recognized as performance obligations are satisfied. When sales commissions or other costs to obtain contracts with customers are considered incremental and recoverable, those costs are deferred and then amortized as selling and marketing expenses on a straight-line basis over an estimated period of benefit.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are expensed as they are incurred. Research and development expenses consist primarily of costs associated with the pre-clinical development and clinical trials of our product candidates. For the nine September 30, 2019 2018, $382,000 $318,000,
Earnings Per Share, Policy [Policy Text Block]	Income (Loss) per Common Share Basic income (loss) per common share is computed by dividing total net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period. Weighted average shares outstanding includes outstanding “prefunded” warrants with an exercise price of $0.0001. 4 For periods of net income when the effects are dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted average number of shares outstanding and the dilutive impact of all dilutive potential common shares. Dilutive potential common shares consist primarily of convertible preferred stock, stock options, restricted stock units and common stock purchase warrants. The dilutive impact of potential common shares resulting from common stock equivalents is determined by applying the treasury stock method. Our unvested restricted shares contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; the calculation of basic and diluted income per share excludes net income attributable to the unvested restricted shares from the numerator and excludes the impact of the shares from the denominator. For all periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive due to the net losses; accordingly, diluted loss per share is the same as basic loss per share for the three nine September 30, 2019 2018. 7.3 0.5 three nine September 30, 2019 2018,
Share-based Payment Arrangement [Policy Text Block]	Share-Based Compensation We account for share-based compensation at fair value. Share-based compensation cost for stock options and stock purchase warrants is generally determined at the grant date using an option pricing model that uses Level 3
Goodwill and Intangible Assets, Policy [Policy Text Block]	Intangible and Long-Lived Assets We assess impairment of our long-lived assets using a "primary asset" approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not not No three nine September 30, 2019 2018.
Income Tax, Policy [Policy Text Block]	Income Taxes We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is “more likely than not”
Lessee, Leases [Policy Text Block]	Leases We determine if an arrangement is or contains a lease at its inception. We have made accounting policy elections whereby we (i) do not 12 not ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Rent expense is recognized on a straight-line basis over the lease term. See Note 5,
New Accounting Pronouncements, Policy [Policy Text Block]	Significant New Accounting Pronouncements Recently Adopted Guidance In February 2016, ASU, No. 2016 02, December 15, 2018 may January 1, 2019 not not $53,000 $75,700 In June 2018, ASU 2018 07, ASC 718, 1 2 3 December 15, 2018. January 1, 2019. not Unadopted Guidance In June 2016, ASU No. 2016 13, December 15, 2019, not In August 2018, ASU 2018 13, 820 December 15, 2019 In August 2018, ASU 2018 15, December 15, 2019 We have reviewed other recent accounting pronouncements and concluded that they are either not no

Note 3 - Fair Value Measureme_2

Note 3 - Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Level 1 Level 2 Level 3 Total Liabilities Liability classified stock purchase warrants $ - $ - $ 583,734 $ 583,734 Balance at December 31, 2018 $ - $ - $ 583,734 $ 583,734 Liability classified stock purchase warrants $ - $ - $ 166,938 $ 166,938 Balance at September 30, 2019 $ - $ - $ 166,938 $ 166,938
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Mark-to-market liabilities - stock purchase warrants Balance at December 31, 2018 $ 583,734 Change in fair value - gain (416,796 ) Balance at September 30, 2019 $ 166,938 Mark-to-market liabilities - stock purchase warrants Balance at December 31, 2017 $ 3,852,882 Change in fair value - gain (1,805,319 ) Balance at September 30, 2018 $ 2,047,563

Note 4 - Stockholders' Equity (

Note 4 - Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended September 30, 2019 2018 Research and development expenses $ - $ 22,917 General and administrative expenses 294,600 111,778 Total $ 294,600 $ 134,695 Nine Months Ended September 30, 2019 2018 Research and development expenses $ 200,337 $ 110,417 General and administrative expenses 561,007 459,856 Total $ 761,344 $ 570,273
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Options Weighted-Average Exercise Price Weighted-Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding at January 1, 2019 81,674 $ 215.60 5.1 $ - Granted 228,183 $ 7.78 Exercised - $ - $ - Forfeited (10,127 ) $ 86.07 Outstanding at September 30, 2019 299,730 $ 61.78 7.9 $ - Exercisable at September 30, 2019 206,347 $ 86.15 7.2 $ -
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Range of Exercise Prices Number of Options Outstanding Weighted-Average Exercise Price Weighted-Average Remaining Contractual Life (in years) Aggregate Intrinsic Value $5.90 - $6.00 58,010 $ 5.99 9.3 $ - $7.20 - $8.80 162,593 $ 8.51 9.2 - $22.20 - $99.20 36,138 $ 33.20 5.6 - $107.40 - $1,102.41 42,989 $ 362.61 2.9 - 299,730 $ 61.78 7.9 $ -
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Nine Months Ended September 30, 2019 2018 Annual dividend - - Expected life (in years) 4.8 - 5.5 2.5 - 5.3 Risk free interest rate 1.8% - 2.5% 2.7% - 2.8% Expected volatility 97% - 115% 97% - 117%
Schedule of Share-based Compensation, Warrant Activity [Table Text Block]	Range of Exercise Prices Number of Warrants Outstanding Range of Expiration Dates $0.0001 1,048,166 perpetual $2.19 - $2.70 6,538,035 December 2020 - August 2024 $3.38 - $17.50 406,223 October 2023 - July 2024 $22.20 - $782.60 26,479 October 2019 - July 2023 8,018,903

Note 5 - Commitments and Cont_2

Note 5 - Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Lease, Cost [Table Text Block]	Operating lease cost $ 141,300 Variable lease cost 23,200 Sublease income (86,100 ) Total net lease cost $ 78,400
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Future undiscounted cash flows: Remainder 2019 $ 11,845 2020 52,482 2021 53,498 2022 55,118 2023 56,920 2024 13,390 Total 243,253 Discount factor (59,733 ) Lease liability 183,520 Less current liability (30,888 ) Non-current lease liability $ 152,632

Note 1 - Organization, Busine_2

Note 1 - Organization, Business and Financial Condition (Details Textual)	Jul. 17, 2019	Jul. 31, 2019USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)
Number of Operating Segments			1
Proceeds from Issuance or Sale of Equity, Net of Issuance Costs			$ 6,552,842
Underwritten Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Net of Issuance Costs		$ 6,600,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	20

Note 2 - Significant Accounti_2

Note 2 - Significant Accounting Policies and Basis of Presentation (Details Textual) - USD ($) $ / shares in Units, shares in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019	Sep. 30, 2018	Jul. 31, 2019	Jan. 01, 2019
Cost Reimbursements from SBIR Grant as Offset to Research and Development Expenses		$ 382,000	$ 318,000
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		7.3	0.5
Asset Impairment Charges, Total	$ 0	$ 0	$ 0
Operating Lease, Right-of-Use Asset	204,300	204,300
Operating Lease, Liability, Total	$ 183,520	$ 183,520
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset					$ 53,000
Operating Lease, Liability, Total					$ 75,700
Underwritten Public Offering [Member] | Prefunded Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.0001

Note 3 - Fair Value Measureme_3

Note 3 - Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Fair value of liabilities	$ 166,938	$ 583,734
Stock Purchase Warrants [Member]
Liability classified stock purchase warrants	166,938	583,734
Fair Value, Inputs, Level 1 [Member]
Fair value of liabilities
Fair Value, Inputs, Level 1 [Member] | Stock Purchase Warrants [Member]
Liability classified stock purchase warrants
Fair Value, Inputs, Level 2 [Member]
Fair value of liabilities
Fair Value, Inputs, Level 2 [Member] | Stock Purchase Warrants [Member]
Liability classified stock purchase warrants
Fair Value, Inputs, Level 3 [Member]
Fair value of liabilities	166,938	583,734
Fair Value, Inputs, Level 3 [Member] | Stock Purchase Warrants [Member]
Liability classified stock purchase warrants	$ 166,938	$ 583,734

Note 3 - Fair Value Measureme_4

Note 3 - Fair Value Measurements - Activity for Items Measured at Fair Value on a Recurring Basis (Details) - Stock Purchase Warrants [Member] - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Balance	$ 583,734	$ 3,852,882
Change in fair value - gain	(416,796)	(1,805,319)
Balance	$ 166,938	$ 2,047,563

Note 4 - Stockholders' Equity_2

Note 4 - Stockholders' Equity (Details Textual) - USD ($)	1 Months Ended					3 Months Ended		9 Months Ended
	Jul. 31, 2019	Feb. 28, 2019	Aug. 31, 2017	Dec. 31, 2016	May 31, 2016	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period								10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant								8,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value								$ 3.45	$ 15.40
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount								$ 384,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition								255 days
Additional Research and Development Expense Due to Modifications							$ 102,000
Stock Issued During Period, Value, RSU and Option Exercises, Net of Forfeitures
Proceeds from Warrant Exercises								$ 131
Proceeds from Issuance or Sale of Equity, Net of Issuance Costs								$ 6,552,842
Series A 4.5% Convertible Preferred Stock [Member]
Conversion of Stock, Shares Converted	334,809
Stock Issued During Period, Shares, Conversion of Convertible Securities	65,077
Underwritten Public Offering [Member]
Number of Prefunded Units Sold	2,361,462
Number of Units Sold	416,315
Unit Price	$ 2.70
Proceeds from Issuance or Sale of Equity, Total	$ 7,500,000
Number of Common Stock in Each Unit	1
Number of Short-term Warrants in Each Unit	1
Number of Long-term Warrants in Each Unit	1
Number of Prefunded Warrants in Each Prefunded Unit	1
Number of Short-term Warrants in Each Prefunded Unit	1
Number of Long-term Warrants in Each Prefunded Unit	1
Proceeds from Issuance or Sale of Equity, Net of Issuance Costs	$ 6,600,000
Private Placement [Member] | Series A 4.5% Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues				200,000
Preferred Stock, Dividend Rate, Percentage				4.50%
Convertible Preferred Stock, Issuable Upon Conversion of All Shares				38,873
Over-Allotment Option [Member]
Underwriters, Additional Common Shares Authorized to Purchase	416,666
Underwriters, Additional Warrants Authorized to Purchase	416,666
Stock Purchase Warrants [Member]
Class of Warrant or Right, Issued During Period		25,000	112,500		87,309
Class of Warrant or Right, Outstanding								149,136
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 6
Class of Warrant or Right, Granted During Period, Weighted Average Grant Date Fair Value		$ 3.80
Class of Warrant or Right, Vesting Percentage on Grant		25.00%
Class of Warrant or Right, Vesting Percentage on Completion of Initial Services		75.00%
Warrants and Rights Outstanding, Term		2 years 182 days
Stock Purchase Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input		0
Stock Purchase Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input		0.025
Stock Purchase Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input		1.1
Short-term Warrants [Member] | Underwritten Public Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.70
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	3,194,443
Long-term warrants [Member] | Underwritten Public Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.70
Warrants and Rights Outstanding, Term	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	3,194,443
Prefunded Warrants [Member]
Class of Warrant or Right, Exercised During Period								1,313,296
Proceeds from Warrant Exercises								$ 100
Prefunded Warrants [Member] | Underwritten Public Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.0001
Equity Classified Warrants [Member] | Underwritten Public Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 3.375
Warrants and Rights Outstanding, Term	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	222,223
Restricted Stock Units (RSUs) [Member]
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount								$ 22,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition								292 days
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted								4,904	2,253
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value								$ 5.90	$ 22.20
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value								$ 6,400
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance								5,467
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Grant Date Fair Value								$ 29.62
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding								$ 10,400
Stock Issued During Period, Shares, RSU and Option Exercises, Net of Forfeitures								1,127
Stock Issued During Period, Value, RSU and Option Exercises, Net of Forfeitures								$ 10,400
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised								0
Restricted Stock [Member]
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount								$ 71,300
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition								292 days
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted								15,689	2,253
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value								$ 5.95	$ 22.20
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Grant Date Fair Value								$ 9.73
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding								$ 14,500
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance								11,972
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Ending Balance								$ 5.95

Note 4 - Stockholders' Equity -

Note 4 - Stockholders' Equity - Share-based Compensation Expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share-based compensation expense	$ 294,600	$ 134,695	$ 761,344	$ 570,273
Research and Development Expense [Member]
Share-based compensation expense		22,917	200,337	110,417
General and Administrative Expense [Member]
Share-based compensation expense	$ 294,600	$ 111,778	$ 561,007	$ 459,856

Note 4 - Stockholders' Equity_3

Note 4 - Stockholders' Equity - Summary of Stock Option Activity (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Options Outstanding (in shares)	81,674
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 215.60
Weighted- average remaining contractual life (Year)	7 years 328 days	5 years 36 days
Options Granted (in shares)	228,183
Options Granted, Weighted Average Exercise Price (in dollars per share)	$ 7.78
Options Exercised (in shares)
Options Exercised, Weighted Average Exercise Price (in dollars per share)
Options Forfeited/Expired (in shares)	(10,127)
Options Forfeited/Expired, Weighted Average Exercise Price (in dollars per share)	$ 86.07
Options Outstanding (in shares)	299,730	81,674
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 61.78	$ 215.60
Options Exercisable (in shares)	206,347
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 86.15
Options Exercisable, Weighted Average Remaining Contractual Life (Year)	7 years 73 days

Note 4 - Stockholders' Equity_4

Note 4 - Stockholders' Equity - Stock Options by Exercise Price Range (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Number of options outstanding (in shares)	299,730
Weighted- average exercise price (in dollars per share)	$ 61.78	$ 215.60
Weighted- average remaining contractual life (Year)	7 years 328 days	5 years 36 days
Aggregate intrinsic value
Range One [Member]
Range of exercise prices, lower limit (in dollars per share)	$ 5.90
Range of exercise prices, upper limit (in dollars per share)	$ 6
Number of options outstanding (in shares)	58,010
Weighted- average exercise price (in dollars per share)	$ 5.99
Weighted- average remaining contractual life (Year)	9 years 109 days
Aggregate intrinsic value
Range Two [Member]
Range of exercise prices, lower limit (in dollars per share)	$ 7.20
Range of exercise prices, upper limit (in dollars per share)	$ 8.80
Number of options outstanding (in shares)	162,593
Weighted- average exercise price (in dollars per share)	$ 8.51
Weighted- average remaining contractual life (Year)	9 years 73 days
Aggregate intrinsic value
Range Three [Member]
Range of exercise prices, lower limit (in dollars per share)	$ 22.20
Range of exercise prices, upper limit (in dollars per share)	$ 99.20
Number of options outstanding (in shares)	36,138
Weighted- average exercise price (in dollars per share)	$ 33.20
Weighted- average remaining contractual life (Year)	5 years 219 days
Aggregate intrinsic value
Range Four [Member]
Range of exercise prices, lower limit (in dollars per share)	$ 107.40
Range of exercise prices, upper limit (in dollars per share)	$ 1,102.41
Number of options outstanding (in shares)	42,989
Weighted- average exercise price (in dollars per share)	$ 362.61
Weighted- average remaining contractual life (Year)	2 years 328 days
Aggregate intrinsic value

Note 4 - Stockholders' Equity_5

Note 4 - Stockholders' Equity - Fair Value Assumptions for Stock Options (Details)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Annual dividend
Minimum [Member]
Expected life (Year)	4 years 292 days	2 years 182 days
Risk free interest rate	1.80%	2.70%
Expected volatility	97.00%	97.00%
Maximum [Member]
Expected life (Year)	5 years 182 days	5 years 109 days
Risk free interest rate	2.50%	2.80%
Expected volatility	115.00%	117.00%

Note 4 - Stockholders' Equity_6

Note 4 - Stockholders' Equity - Summary of Warrant Activity (Details) - Stock Purchase Warrants [Member]	9 Months Ended
	Sep. 30, 2019$ / sharesshares
Number of warrants outstanding (in shares) | shares	8,018,903
Range One [Member]
Lower exercise price range (in dollars per share)	$ 0.0001
Upper range of exercise prices (in dollars per share)	$ 0.0001
Number of warrants outstanding (in shares) | shares	1,048,166
Expiration dates	perpetual
Range Two [Member]
Lower exercise price range (in dollars per share)	$ 2.19
Upper range of exercise prices (in dollars per share)	$ 2.70
Number of warrants outstanding (in shares) | shares	6,538,035
Range Two [Member] | Minimum [Member]
Expiration dates	December 2020
Range Two [Member] | Maximum [Member]
Expiration dates	August 2024
Range Three [Member]
Lower exercise price range (in dollars per share)	$ 3.38
Upper range of exercise prices (in dollars per share)	$ 17.50
Number of warrants outstanding (in shares) | shares	406,223
Range Three [Member] | Minimum [Member]
Expiration dates	October 2023
Range Three [Member] | Maximum [Member]
Expiration dates	July 2024
Range Four [Member]
Lower exercise price range (in dollars per share)	$ 22.20
Upper range of exercise prices (in dollars per share)	$ 782.60
Number of warrants outstanding (in shares) | shares	26,479
Range Four [Member] | Minimum [Member]
Expiration dates	October 2019
Range Four [Member] | Maximum [Member]
Expiration dates	July 2023

Note 5 - Commitments and Cont_3

Note 5 - Commitments and Contingencies (Details Textual)	9 Months Ended
	Sep. 30, 2019USD ($)ft²	Sep. 30, 2018USD ($)
Sublease Income	$ 86,100
Operating Lease, Expense	164,500	$ 134,100
Operating Lease, Right-of-Use Asset	204,300
Operating Lease, Liability, Total	$ 183,520
Lessee, Operating Lease, Discount Rate	12.75%
Short-term Leases [Member]
Operating Lease, Expense	$ 83,900
UNITED STATES
Number of Facilities	1
CHINA
Number of Facilities	1
Area of Real Estate Property | ft²	11,300
Lease Monthly Payment	$ 4,400
Germantown, MD [Member]
Area of Real Estate Property | ft²	1,500
Lease Monthly Payment	$ 5,700
Lessee, Operating Lease, Term of Contract	1 year

Note 5 - Commitments and Cont_4

Note 5 - Commitments and Contingencies - Lease Cost (Details)	9 Months Ended
	Sep. 30, 2019USD ($)
Operating lease cost	$ 141,300
Variable lease cost	23,200
Sublease income	(86,100)
Total net lease cost	$ 78,400

Note 5 - Commitments and Cont_5

Note 5 - Commitments and Contingencies - Maturities of Operating Lease (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Remainder 2019	$ 11,845
2020	52,482
2021	53,498
2022	55,118
2023	56,920
2024	13,390
Total	243,253
Discount factor	(59,733)
Lease liability	183,520
Less current liability	(30,888)
Non-current lease liability	$ 152,632

Note 6 - Related Party Receiv_2

Note 6 - Related Party Receivable (Details Textual) - Chief Scientific Officer [Member] - Repayment Agreement of Improperly Expense Reimbursement [Member] - USD ($)	Aug. 10, 2016	Sep. 30, 2019
Due from Related Parties, Term	6 years
Due from Related Parties, Total	$ 658,000	$ 229,000
Due from Related Party, Discount	$ 199,000